Lindis Biotech GmbH

LINDIS Biotech GmbH announced CHMP's positive opinion recommending Korjuny (catumaxomab) for malignant ascites in EpCAM-positive carcinomas, pending EC approval. Korjuny, a trifunctional antibody, could be the only drug for specific cancer-directed treatment of malignant ascites, with potential in other indications like bladder cancer.

Catumaxomab, now branded as Korjuny, received a positive opinion from the EMA's CHMP for treating malignant ascites, marking its return after a decade off the market. Korjuny, a bispecific and trifunctional antibody, engages Epcam on cancer cells and CD3 on T cells, recruiting immune cells to destroy tumor cells. The EMA approval is limited to malignant ascites, but ongoing trials aim to expand its use, including a global phase III trial in advanced gastric cancer.